Literature DB >> 29271990

MiR-638 inhibits cervical cancer metastasis through Wnt/β-catenin signaling pathway and correlates with prognosis of cervical cancer patients.

H Wei1, J-J Zhang, Q-L Tang.   

Abstract

OBJECTIVE: MiR‑638 has been demonstrated to be correlated with several tumor progressions. However, the exact role of miRNA-638 in cervical cancer (CC) has not been investigated. The aim of present study was to explore the prognostic value of miR-638 in patients with CC and analyze molecular mechanisms of miR-638 in CC progression. PATIENTS AND METHODS: Real-time quantitative RT-PCR was performed to measure miR-638 expression level in 196 paired of CC and matched normal tissues, CC cell lines. The correlation of miR-638 with clinicopathological features and prognosis was analyzed. Furthermore, the effects of miR-638 on tumorigenicity of CC cells were evaluated by functional assays. Finally, Western blot was used to evaluate the activation of Wnt/β-catenin signaling pathway.
RESULTS: We found that miR-638 expression was downregulated in CC tissues and cell lines compared with the adjacent normal tissues and normal cell lines. In addition, low expressions of miR-638 were significantly associated with advanced FIGO stage (p =0.007), lymph node metastasis (p = 0.018) and vascular invasion (p = 0.002). Moreover, the results of Kaplan-Meier method showed that CC patients with lower miR-638 expression had significantly poorer overall survival (p = 0.0023) and progression-free survival (p = 0.0005). In a multivariate Cox model, we found that miR-638 expression was an independent prognostic factor for both overall survival and progression-free survival in patients with CC (both p = 0.001). In vitro assay showed that miR-638 overexpression suppressed cell migration and invasion of HeLa cells. The results of Western blot indicated that over-expression of miR-638 inhibited the activation of Wnt/β-catenin signaling pathway.
CONCLUSIONS: Our findings firstly showed that miR-638 might serve as a tumor suppressor. In the future, miR-638 might be regarded as a therapeutic target and a potential prognostic factor in human CC.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29271990     DOI: 10.26355/eurrev_201712_13999

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  11 in total

1.  miR-638 represses the stem cell characteristics of breast cancer cells by targeting E2F2.

Authors:  Qiu-Yan Lin; Jia-Qi Wang; Li-Li Wu; Wei-E Zheng; Pei-Rui Chen
Journal:  Breast Cancer       Date:  2019-08-13       Impact factor: 4.239

2.  MicroRNA-214 promotes the proliferation, migration and invasion of gastric cancer MKN28 cells by suppressing the expression of Dact2.

Authors:  Lei Zhao; Weiwei Fan; Yujing Fan; Shanling Gao
Journal:  Exp Ther Med       Date:  2018-09-19       Impact factor: 2.447

3.  MicroRNA-638 inhibits the progression of breast cancer through targeting HOXA9 and suppressing Wnt/β-cadherin pathway.

Authors:  Qian Xu; Qianqian Zhang; Mengli Dong; Yuan Yu
Journal:  World J Surg Oncol       Date:  2021-08-20       Impact factor: 2.754

4.  MicroRNA-204 may participate in the pathogenesis of hypoxic-ischemic encephalopathy through targeting KLLN.

Authors:  Ronglin Chen; Meixia Wang; Shaopin Fu; Feng Cao; Pengkai Duan; Jiefu Lu
Journal:  Exp Ther Med       Date:  2019-08-26       Impact factor: 2.447

5.  Identification and validation of a miRNA-based prognostic signature for cervical cancer through an integrated bioinformatics approach.

Authors:  Yumei Qi; Yo-Liang Lai; Pei-Chun Shen; Fang-Hsin Chen; Li-Jie Lin; Heng-Hsiung Wu; Pei-Hua Peng; Kai-Wen Hsu; Wei-Chung Cheng
Journal:  Sci Rep       Date:  2020-12-17       Impact factor: 4.379

6.  Hsa_circ_0001869 promotes NSCLC progression via sponging miR-638 and enhancing FOSL2 expression.

Authors:  Pei Xu; Lei Wang; Xiao Xie; Fengqing Hu; Qi Yang; Rui Hu; Lianyong Jiang; Fangbao Ding; Ju Mei; Jianhui Liu; Haibo Xiao
Journal:  Aging (Albany NY)       Date:  2020-11-20       Impact factor: 5.682

7.  Prognostic and clinicopathological significance of miR-638 in cancer patients: A meta-analysis.

Authors:  Lixia Hu; Mengqin Huang; Qianqian Yuan; Fanliang Kong
Journal:  Medicine (Baltimore)       Date:  2021-04-16       Impact factor: 1.817

Review 8.  The role of miRNAs in the invasion and metastasis of cervical cancer.

Authors:  Jin-Yan Wang; Li-Juan Chen
Journal:  Biosci Rep       Date:  2019-03-15       Impact factor: 3.840

9.  Methylation‑associated silencing of miR‑638 promotes endometrial carcinoma progression by targeting MEF2C.

Authors:  Jianjiao Ni; Shanhui Liang; Boer Shan; Wenjuan Tian; Huaying Wang; Yulan Ren
Journal:  Int J Mol Med       Date:  2020-03-16       Impact factor: 4.101

10.  Circular RNA TADA2A promotes proliferation and migration via modulating of miR‑638/KIAA0101 signal in non‑small cell lung cancer.

Authors:  Ye Zhang; Hongmin Yao; Ying Li; Lu Yang; Liang Zhang; Jinxin Chen; Yong Wang; Xia Li
Journal:  Oncol Rep       Date:  2021-07-23       Impact factor: 3.906

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.